Selvedge Venture

Mesh Bio is a digital health startup focused on enhancing chronic disease management through predictive analytics. The company collaborates with healthcare providers and stakeholders to deliver innovative solutions that improve health screening and disease management processes. Its multidimensional health intelligence platform automates the generation of health screening reports, increasing accuracy and aiding in the interpretation of laboratory results. By translating clinical data into actionable insights, Mesh Bio enables healthcare providers to conduct holistic patient assessments, ultimately helping patients better manage their health, lifestyle, and associated disease risks.

BIOS Health is a pioneering company focused on developing neural digital therapies by leveraging data from the human nervous system. By identifying neural biomarkers that correlate nerve activity to specific medical conditions, BIOS aims to revolutionize precision medicine. Their research offers the potential for innovative treatments for a range of chronic diseases, including hypertension, diabetes, and neurodegenerative disorders such as Parkinson's and Alzheimer's. Co-founded by experts from Cambridge University, the team includes professionals from diverse fields such as neuroscience, machine learning, and biotechnology. Additionally, BIOS is working on prosthetic connectors that standardize connections between bionic devices and neural systems, facilitating neural control and feedback for amputees. This dual approach positions BIOS at the forefront of improving the quality of life for individuals with chronic conditions and those requiring prosthetic solutions.

Carbometrics is a specialized chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Building on over 20 years of research led by Professor Anthony Davis at the University of Bristol, the company aims to develop a robust and accurate glucose sensing platform. This technology is intended to create a market-leading Continuous Glucose Monitoring (CGM) solution, helping individuals with diabetes manage their condition more effectively. Carbometrics was established following the founders' successful sale of their previous company, Ziylo, to Novo Nordisk, which is utilizing a similar platform for the development of smart insulins.

MultiOmic Health is an AI-driven start-up specializing in drug discovery for metabolic syndrome-related diseases. The company collaborates with selected healthcare providers to collect and analyze de-identified patient data and bio-samples. Its MOHSAIC® platform integrates multi-omics analysis with computational systems biology modeling and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies, facilitating the creation of new therapeutic and diagnostic research and development programs. By focusing on precision medicine, MultiOmic Health aims to improve treatment options for patients suffering from metabolic syndrome.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Oxford Medical Products is focused on developing an innovative gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This technology is designed to expand rapidly upon ingestion, providing a lasting feeling of satiety. Over time, the capsule breaks down gradually and passes naturally through the digestive system. Comprising a team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to providing a safe, effective, and affordable solution to one of the world's pressing health issues.

MultiOmic Health is an AI-driven start-up specializing in drug discovery for metabolic syndrome-related diseases. The company collaborates with selected healthcare providers to collect and analyze de-identified patient data and bio-samples. Its MOHSAIC® platform integrates multi-omics analysis with computational systems biology modeling and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies, facilitating the creation of new therapeutic and diagnostic research and development programs. By focusing on precision medicine, MultiOmic Health aims to improve treatment options for patients suffering from metabolic syndrome.

Kytopen is a developer of a cell therapy platform that focuses on the non-viral delivery of molecules into challenging immune cells. The company's innovative technology integrates microfluidics and automation to streamline the delivery process, making it faster, easier, and more cost-effective. Kytopen's automated cell engineering platform enables researchers to produce healthy and functional engineered cells rapidly, maintaining their health and functionality. By combining continuous fluid flow with electric fields, Kytopen enhances the efficiency of payload delivery to primary cells, supporting advancements in biology and paving the way for innovative cell and gene therapies.

Sanome is focused on addressing the growing demand for healthcare services by enhancing early detection and prevention strategies. The company has developed a predictive analytics tool that aids clinicians in identifying patient health changes earlier, thereby improving decision-making in clinical settings. By integrating healthcare data with advanced artificial intelligence and biophysical biomarkers, including at-home composite tests, Sanome's platform provides actionable clinical insights. This approach enables healthcare providers to detect potential health issues before they escalate, ultimately leading to better patient outcomes and increased operational efficiency. The company's long-term vision includes creating a human digital twin that continuously monitors individual health, informing clinicians about significant changes through its Clinical Co-pilot.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Yuri specializes in designing and manufacturing hardware for the aviation and aerospace industry, focusing on applications in microgravity research and experiments. The company provides an end-to-end space mission platform that includes services such as mission definition, hardware selection and development, as well as launch and return logistics. Additionally, Yuri supports researchers with a variety of advanced scientific services, including 3D cell culture growth, human disease modeling, protein and molecule analysis, synthetic biology, plant biology studies, and nanofluidics. This comprehensive approach enables researchers to access a quick and cost-effective combination of experimental hardware, facilities, and microgravity platforms.

MultiOmic Health is an AI-driven start-up specializing in drug discovery for metabolic syndrome-related diseases. The company collaborates with selected healthcare providers to collect and analyze de-identified patient data and bio-samples. Its MOHSAIC® platform integrates multi-omics analysis with computational systems biology modeling and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies, facilitating the creation of new therapeutic and diagnostic research and development programs. By focusing on precision medicine, MultiOmic Health aims to improve treatment options for patients suffering from metabolic syndrome.

Oxford Medical Products is focused on developing an innovative gastro-retentive hydrogel technology aimed at addressing weight loss challenges. The company has created a self-expanding capsule that occupies space in the stomach, effectively reducing hunger and promoting significant weight loss. This technology is designed to expand rapidly upon ingestion, providing a lasting feeling of satiety. Over time, the capsule breaks down gradually and passes naturally through the digestive system. Comprising a team of scientists, medical professionals, and entrepreneurs, Oxford Medical Products is dedicated to providing a safe, effective, and affordable solution to one of the world's pressing health issues.

Avro Life Science is a Canadian company focused on developing transdermal drug delivery systems, specifically medicated skin patches designed for the pediatric and elderly populations. Utilizing a novel biopolymer as a platform, Avro's technology enables passive delivery of small molecules and drugs directly into the bloodstream, allowing for a slow-release mechanism. This innovative approach aims to enhance medication accessibility while minimizing the impact on the liver, ultimately improving health outcomes and quality of life for its patients.

Exogene is a biotechnology company focused on advancing T-cell receptor (TCR)-based cancer immunotherapies for solid tumors. By integrating deep learning with high-throughput TCR-antigen screening, Exogene aims to efficiently identify new tumor targets that are common among cancer patients. The company is developing a computational platform designed to discover effective and safe TCRs against these targets, facilitating their therapeutic application. This innovative approach allows for the rapid and cost-effective development of TCR-based immunotherapies, ultimately supporting healthcare providers in creating cell therapies that enhance the immune system's ability to combat cancer.

PharmaCCX, Inc. is a company that operates a market access platform designed to streamline the pricing and procurement of medicines for healthcare payers, thereby facilitating quicker patient access to necessary treatments. The platform primarily supports oncology pharmaceutical companies and various healthcare systems in the United States and Europe. Founded in 2017 and headquartered in Boston, Massachusetts, PharmaCCX also maintains offices in Stockholm, Sweden; San Mateo, California; and Zug, Switzerland. The company's software enhances the efficiency of market access teams within pharmaceutical companies and payers, enabling them to effectively plan, negotiate, and manage innovative payment models.